K4 Elite logo K4 Elite
Home / Peptide Library / Exenatide
Extensively Studied

Exenatide

GLP & Metabolic · ['Exendin-4', 'AC2993', 'Byetta (brand)', 'Bydureon (brand)']

A 39-amino-acid GLP-1 receptor agonist derived from exendin-4, studied for glucose-dependent insulin secretion, appetite signaling, and its resistance to enzymatic degradation.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Molecular Formula
C184H282N50O60S
Molecular Weight
4186.6 g/mol
PubChem
CID 45588096 ↗
Research Level
Extensively Studied
Browse the store →
Exenatide chemical structure

Exenatide is the synthetic form of exendin-4, a peptide originally identified in the salivary secretions of the Gila monster (Heloderma suspectum). It functions as a GLP-1 receptor agonist and shares roughly 53% sequence identity with human GLP-1 while resisting cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4).

Because of this enzymatic resistance, exenatide displays a longer active half-life than native GLP-1 in reported study systems, making it a frequently used reference incretin mimetic. Investigators employ it to study glucose-dependent insulin release, glucagon suppression, gastric emptying, and central appetite circuits.

The information below summarizes published scientific literature for reference purposes only and reflects findings reported by researchers.

Exenatide binds and activates the GLP-1 receptor, elevating intracellular cyclic AMP in pancreatic beta cells. In study models this potentiates insulin secretion only when glucose is elevated, a glucose-dependent action that investigators associate with a low intrinsic hypoglycemia signal.

Its N-terminal structure resists DPP-4 cleavage, which prolongs receptor engagement compared with native GLP-1. Reported work also describes activation of GLP-1 receptors in the central nervous system linked to satiety and delayed gastric emptying.

  • Glucose-dependent insulin secretion in metabolic and islet models
  • DPP-4 resistance and incretin pharmacokinetics
  • Central appetite and body-weight regulation research
  • Neuroprotection studies in Parkinson's disease models
  • Gastric emptying and gastrointestinal motility investigations
  • Beta-cell preservation and proliferation exploratory work
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Aviles-Olmos and colleagues (J Clin Invest 2013) conducted an exploratory clinical study administering exenatide to participants with Parkinson's disease, reporting motor and cognitive assessment differences versus a control group; the authors framed this as hypothesis-generating research into GLP-1 signaling in the brain.

DeFronzo et al. (Diabetes Care 2005) reported a randomized controlled trial of exenatide added to metformin in adults with type 2 diabetes, documenting reductions in glycated hemoglobin and body weight relative to placebo. These are summarized purely as published human research findings.

Foundational pharmacology by Eng and colleagues characterized exendin-4 isolated from Heloderma venom and its agonism at the GLP-1 receptor in early laboratory studies.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

LiraglutideCaution
Both act on the GLP-1 receptor; concurrent study use produces redundant receptor activation not characterized in the literature.
MetforminCompatible
Combination has been studied in diabetes trials with complementary mechanisms reported.
SulfonylureasCaution
Literature notes an increased glucose-lowering signal when combined, warranting monitoring in research settings.
InsulinCaution
Additive glucose-lowering effects are reported in study contexts.
  1. DeFronzo RA et al. Effects of Exenatide on Glycemic Control and Weight in Type 2 Diabetes. Diabetes Care 2005
  2. Aviles-Olmos I et al. Exenatide and the Treatment of Patients with Parkinson's Disease. J Clin Invest 2013
  3. Eng J et al. Isolation and Characterization of Exendin-4. J Biol Chem 1992
  4. PubChem Compound Summary: Exenatide (CID 45588096)
What is exenatide?
It is a synthetic version of exendin-4, a naturally occurring peptide from Gila monster saliva that activates the GLP-1 receptor and resists rapid enzymatic breakdown.
Why is exenatide resistant to DPP-4?
Its N-terminal amino-acid arrangement differs from native GLP-1 in a way that blocks cleavage by the DPP-4 enzyme, extending its active window in reported study models.
What has exenatide been studied for beyond metabolism?
Beyond glucose regulation, investigators have explored exenatide in neuroprotection models, including exploratory clinical work in Parkinson's disease.
Is this material sold for human or veterinary use?
No. It is offered strictly as a research-use-only reference compound and is not intended for human consumption, medical treatment, or veterinary application.
Are the effects described here guaranteed?
No. All statements summarize published research and are attributed to the investigators. They are not benefit or efficacy claims for any individual.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.